JP2018536433A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536433A5
JP2018536433A5 JP2018541546A JP2018541546A JP2018536433A5 JP 2018536433 A5 JP2018536433 A5 JP 2018536433A5 JP 2018541546 A JP2018541546 A JP 2018541546A JP 2018541546 A JP2018541546 A JP 2018541546A JP 2018536433 A5 JP2018536433 A5 JP 2018536433A5
Authority
JP
Japan
Prior art keywords
protein
hbv
nucleotide sequence
antigenic fragment
arenavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018541546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536433A (ja
JP6914950B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/076591 external-priority patent/WO2017076988A1/en
Publication of JP2018536433A publication Critical patent/JP2018536433A/ja
Publication of JP2018536433A5 publication Critical patent/JP2018536433A5/ja
Priority to JP2021116562A priority Critical patent/JP2021182922A/ja
Application granted granted Critical
Publication of JP6914950B2 publication Critical patent/JP6914950B2/ja
Priority to JP2023180121A priority patent/JP7777907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018541546A 2015-11-04 2016-11-03 Ｂ型肝炎ウイルスに対するワクチン Active JP6914950B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021116562A JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン
JP2023180121A JP7777907B2 (ja) 2015-11-04 2023-10-19 Ｂ型肝炎ウイルスに対するワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
US62/250,639 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021116562A Division JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン

Publications (3)

Publication Number Publication Date
JP2018536433A JP2018536433A (ja) 2018-12-13
JP2018536433A5 true JP2018536433A5 (OSRAM) 2020-03-26
JP6914950B2 JP6914950B2 (ja) 2021-08-11

Family

ID=57249796

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018541546A Active JP6914950B2 (ja) 2015-11-04 2016-11-03 Ｂ型肝炎ウイルスに対するワクチン
JP2021116562A Pending JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン
JP2023180121A Active JP7777907B2 (ja) 2015-11-04 2023-10-19 Ｂ型肝炎ウイルスに対するワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021116562A Pending JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン
JP2023180121A Active JP7777907B2 (ja) 2015-11-04 2023-10-19 Ｂ型肝炎ウイルスに対するワクチン

Country Status (20)

Country Link
US (2) US11214598B2 (OSRAM)
EP (2) EP4177348A1 (OSRAM)
JP (3) JP6914950B2 (OSRAM)
KR (2) KR20250107977A (OSRAM)
CN (2) CN108779472B (OSRAM)
AU (2) AU2016348675B2 (OSRAM)
CA (1) CA3003557A1 (OSRAM)
DK (1) DK3371316T3 (OSRAM)
ES (1) ES2934698T3 (OSRAM)
FI (1) FI3371316T3 (OSRAM)
HR (1) HRP20221474T1 (OSRAM)
HU (1) HUE060648T2 (OSRAM)
IL (2) IL314371A (OSRAM)
LT (1) LT3371316T (OSRAM)
MX (2) MX2018005569A (OSRAM)
PL (1) PL3371316T3 (OSRAM)
PT (1) PT3371316T (OSRAM)
SG (1) SG11201803474UA (OSRAM)
SI (1) SI3371316T1 (OSRAM)
WO (1) WO2017076988A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2438773T3 (es) 2007-12-27 2014-01-20 Universität Zürich Vectores arenavíricos defectuosos en la replicación
PL3077519T3 (pl) 2013-12-03 2021-10-18 Hookipa Biotech Gmbh Szczepionki CMV
US10722564B2 (en) * 2014-11-13 2020-07-28 Université de Genéve Tri-segmented arenaviruses as vaccine vectors
CA2987155A1 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
PT3373959T (pt) 2015-11-12 2022-08-09 Hookipa Biotech Gmbh Partículas de arenavírus como vacinas contra o cancro
EP4234691A3 (en) 2016-10-14 2023-10-18 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP3986454A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
CA3143421A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
US20220380805A1 (en) * 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
US20240174724A1 (en) 2021-03-23 2024-05-30 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
US20250034213A1 (en) * 2021-04-21 2025-01-30 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) * 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
HU229222B1 (en) * 1998-12-04 2013-09-30 Biogen Idec Ma Inc Cambridge Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
EP1888622A1 (en) 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
NZ600281A (en) * 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
ES2438773T3 (es) * 2007-12-27 2014-01-20 Universität Zürich Vectores arenavíricos defectuosos en la replicación
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
AU2012214394B2 (en) * 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP2806889B1 (en) 2012-01-24 2017-08-16 Sanford Health Polynucleotides for treating oncogenic viral polypeptide positive tumors
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
PL3077519T3 (pl) 2013-12-03 2021-10-18 Hookipa Biotech Gmbh Szczepionki CMV
US10342861B2 (en) 2014-05-27 2019-07-09 University Of Rochester Arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
ES2746150T3 (es) 2014-09-22 2020-03-04 Univ Minnesota Sistema de genética inversa para el virus Pichindé y métodos de uso
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
US10722564B2 (en) 2014-11-13 2020-07-28 Université de Genéve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CA2987155A1 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
EP3365005B1 (en) 2015-10-23 2025-04-09 Institut Pasteur Recombinant mopeia virus and vaccine platform
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
PT3373959T (pt) 2015-11-12 2022-08-09 Hookipa Biotech Gmbh Partículas de arenavírus como vacinas contra o cancro
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
IL314272A (en) 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Similar Documents

Publication Publication Date Title
JP2018536433A5 (OSRAM)
JP2021182922A5 (OSRAM)
FI3371316T3 (fi) Rokotteita hepatiitti b -virusta vastaan
JP6227094B2 (ja) 複製欠損アレナウイルスベクター
Hanke et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
Sominskaya et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes
JP2019519252A5 (OSRAM)
JP2017503482A5 (OSRAM)
JP2017535267A5 (OSRAM)
JP2017527557A5 (OSRAM)
Woo et al. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes
JP2017515508A5 (OSRAM)
Raji et al. Virus-like particles in poultry disease: an approach to effective and safe vaccination
JP2000154152A (ja) 肝炎療剤
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
Krüger et al. Chimeric virus-like particles as vaccines
NZ781654B2 (en) Vaccines against hepatitis b virus
CN1108306A (zh) 羧端带有前表面抗原1决定簇的重组乙肝疫苗
Kosinska et al. MVA-HBVac—A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination
Thomson et al. Genetically modified hepatitis B surface antigen: A powerful vaccine technology for the delivery of disease-associated foreign antigens
Chen et al. HBsAg-vectored DNA vaccines elicit concomitant protective responses to multiple CTL epitopes relevant in human disease.
Prince et al. Methodology Used in DNA-Based Prophylactic and Therapeutic Immunization Against Hepatitis B Virus in Chimpanzees
CN110055228A (zh) 用于乙肝病毒感染的重组巨细胞病毒与应用
HK1192456A (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
HK1151829B (en) Replication-defective arenavirus vectors